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Speciﬁc morphotypic proﬁles of normal and abnormal vaginal ﬂora, including bacterial vaginosis (BV), were
characterized. A prospective study of 350 women yielded concurrent Gram-stain data and clinical assessment
(n=3455 visits). Microbiological proﬁles were constructed by Gram stain. Eight proﬁle deﬁnitions were based
on dichotomizing the levels of Lactobacillus, Gardnerella, and curved, Gram-negative bacillus (Mobiluncus)
morphotypes. Of these, two were rare, and the other six demonstrated a graded association with the clinical
components of BV. The proposed proﬁles from the Gram stain reﬂect the morphotypic categories describing
vaginal ﬂora that may enable clearer elucidation of gynecologic and obstetric outcomes in various populations.
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INTRODUCTION
Bacterial vaginosis (BV) is a pervasive and
persistent problem among women worldwide. It
is a condition or syndrome characterized by a shift
in vaginal microﬂora, whereby hydrogen per-
oxide–producing Lactobacilli are replaced by an
overgrowth of aerobic and anaerobic bacteria,
thus upsetting the ecological balance of the
vagina. Prevalence of BV in the United States
ranges from 10% to 25% in gynecological and
obstetric practices and up to 64% in populations
in sexually transmitted disease (STD) clinics
1,2.I t
is now known to carry potentially serious
consequences including possible associations with
an increased risk of pelvic inﬂammatory disease
3
and preterm delivery
4. BV may contribute to
genital tract shedding of HIV in HIV-infected
women
5, and it may also increase a woman’s risk
of acquisition of HIV and other STDs from an
infected partner
6. Therefore there are many
adverse conditions that are possibly associated
with the presence of BV.
The two common methods for diagnosing BV
are assessment of clinical manifestations and
identiﬁcation of abnormalities in vaginal ﬂora by
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DOI: 10.1080/10647440400020711microscopic examination of Gram-stained slides
of vaginal secretions
7,8. Although physicians tend
to use the clinical criteria for diagnosis
9, the Gram
stain method is the overwhelming method of
choice in research settings and is endorsed by
many as the gold standard
8,10,11. Microﬂora are
substantially heterogeneous whether within a
normal, abnormal, or BV condition. This diag-
nostic uncertainty has implications for clinical
management. In addition, this uncertainty may
underlie the failure of studies of BV to ﬁnd
consistent associations with outcomes and may
help explain why several interventional trials of
BV treatment have had little impact on the
proposed outcome.
We used data from US women who were
evaluated by both clinical and laboratory diag-
nostic methods, to explore whether different
constellations of vaginal ﬂora morphotypes ex-
hibit clinically meaningful distinctions. We
categorized the morphotypes from vaginal Gram
stain into homogeneous groups and correlated
these proﬁles with clinical symptoms that con-
stitute the clinical criteria for BV.
METHODS
Data were analyzed from a cohort of 350 HIV-
uninfected women who were followed in the
Human Immunodeﬁciency Virus Epidemiologi-
cal Research (HER) Study
12, a multi-site
prospective study of women aged 16–55 years
with or at-risk for HIV infection. The HER study
sites included clinical and academic institutions in
four US communities. Recruitment, screening
and enrollment began in April 1993, and follow-
up for the HIV-uninfected women ended in
September 1999. All participants were categor-
ized as having had a history of injection drug use
after 1985 or self-reported, high-risk sexual
behavior according to deﬁned risk criteria. The
protocol was approved by institutional review
boards at the four study sites and the US Centers
for Disease Control and Prevention. All partici-
pants gave their informed consent to participate in
the study.
The visits included a standardized face-to-face
interview that gathered information on medical
symptoms, illnesses, medical procedures, repro-
ductive events, contraceptive use, insurance
status, tobacco, alcohol, drug use, and sexual
behaviors, as well as psychosocial and demo-
graphic factors. A standardized physical exam
followed each interview. The gynecologic exam
included screening for pregnancy, genital tract
inﬂammation, vaginal discharge, and cervical
dysplasia. The laboratory assessment included
blood testing for HIV (enzyme-linked immuno-
sorbent assay) and syphilis serology; Papanicolau
smear; swab of the posterior vaginal fornix used to
prepare a Gram-stained slide; saline and KOH
wet mounts of vaginal secretions for Trichomonas
vaginalis, clue cells, and yeast; vaginal pH assess-
ment using indicator strips (Baxter S/P, Glendale,
CA); whiff-amine test to note if there was a
release of a ﬁshy odor after adding a drop of 10%
KOH to vaginal ﬂuids; a vaginal culture for
Candida and Trichomonas vaginalis; and an en-
docervical culture for Neisseria gonorrhea and an
endocervical culture and direct ﬂuorescent anti-
body test for Chlamydia trachomatis.
Bacterial vaginosis was diagnosed by two
methods: Amsel’s (or clinical) criteria and Nu-
gent’s (or laboratory) criteria. Clinical BV by
Amsel’s criteria
13 assessed by research nurses was
deﬁned by the presence of three or four of the
following signs: positive whiff-amine test, vaginal
pH 44.7, clue cells on wet mount, and abnormal
vaginal discharge. The laboratory deﬁnition is
constructed from Gram-stained scores for Lacto-
bacillus, Gardnerella, and Mobiluncus morphotypes.
All smears of the posterior vaginal fornix were air
dried, ﬁxed in methanol, and then shipped to the
Detroit Medical Center University Laboratories,
Detroit, MI, for Gram-staining. Under oil
immersion (61000 magniﬁcation) each slide
was examined and scored for the aforementioned
morphotypes by a single technologist who was
unaware of the clinical or HIV status of the study
participants. Though there was not a second
technologist reviewing the slides, this one tech-
nician provided consistency of the readings
throughout the entire study period. Each of the
three morphotype scores was quantiﬁed on a scale
of 0 to 4, and these three scores were combined
according to Nugent’s formula
8): Gardnerella
score+(4-Lactobacillus score)+Mobiluncus score/
2, where fractions are rounded up. This formula
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of 7–10 deﬁnes BV; 4–6 is abnormal vaginal ﬂora;
and 0–3 is regarded as normal vaginal ﬂora.
Eight morphotypic proﬁles were constructed
by dichotomizing at the median both Lactobacillus
and Gardnerella scores at 0–2 or 3–4 and
Mobiluncus at 0 or 1–4, and using each possible
combination of the three as one proﬁle (Table 1).
This analysis considered data from HIV-unin-
fected women only, as there are differences in the
natural history of BV in HIV-infected women
14.
Data analysis was restricted to women who had at
least three consecutive visits in which they were
assessed by both laboratory and clinical diagnostic
methods (350 women; 3,455 study visits; median
number of visits per woman was 10, range 2 to
14). The frequency of the eight proﬁles, as well as
the frequency of the two diagnostic methods
within the proﬁles, was assessed. The proﬁles were
cross-tabulated with Nugent scores, clinical BV,
and the individual clinical signs.
RESULTS
The women included in this analysis had a mean
age of 35 years, 54% were African American, 50%
reported intravenous drug use since 1985, and
46% reported having more than ﬁve sex partners
in the previous ﬁve years.
Of the eight morphotypic categories, only the
six (A, C, D, F, G, and H) that occurred with any
appreciable frequency will be discussed (Table 1).
Proﬁle A ﬁt neatly into the Nugent score of 0–3,
which is thought to represent normal vaginal
ﬂora. Proﬁle H ﬁts almost exactly into the
Nugent score of 7–10, which is classic BV. The
other four proﬁles spread across Nugent’s inter-
mediate group (scores 4–6), usually considered as
abnormal. These four proﬁles also overlap with
the normal and BV Nugent categories.
The correlation of proﬁles with the frequency
of laboratory BV shows a progressive increase in
frequency of BV. For example, 48% of women
with Proﬁle C fall into the abnormal Gram stain
category; 85% and 83%, respectively, of Proﬁles
D and F fall into the abnormal ﬂora category;
27% of Proﬁle G falls into the abnormal category
and the remaining 73% falls into the BV
category. Although both clinical and laboratory
BV become relatively more frequent among
abnormal proﬁles, within individual proﬁles the
two diagnostic modes demonstrate notable
differences (Table 1). The more normal proﬁle
(A) was more likely to meet clinical BV criteria
than lab BV criteria; the reverse was true for the
more abnormal proﬁles (G, H). Proﬁle C is a
category representing a sparse ﬂora predomi-
nantly seen after antibiotic treatment and/or
estrogen deﬁciency. Additionally, 34% of proﬁle
D (observed high Gardnerella), which would not
be classiﬁed as BV by the Nugent scoring, had
BV by the clinical deﬁnition. Proﬁles D and F
Table 1 Make-up of the morphotypic proﬁles and the percentage of each within the range of the Nugent scoring, clinical
bacterial vaginosis (BV) and lab BV
Morphotypes* Freq Percentage within each Nugent score Clin BV
{ Lab BV
{
Lact Gard CGNB N 0 1 2 34567891 0 ( % ) ( % )
A 3–4 0–2 0 1579 63 25 9 3 2.5 0.0
B 3–4 0–2 1–4 2 0 0 50 50 0
C 0–2 0–2 0 241 29 22 32 12 4 7.5 0.0
D 3–4 3–4 0 192 15 45 40 34.4 0.0
E 0–2 0–2 1–4 7 0 14 43 29 14 0
F 3–4 3–4 1–4 46 15 33 35 17 41.3 17.4
G 0–2 3–4 0 650 5 22 48 25 48.6 73.1
H 0–2 3–4 1–4 738 1 11 40 34 14 67.8 99.1
3455
*Morphotypes include Lact=Lactobacillus, Gard=Gardnerella, and CGNB=Mobiluncus
{Clinical BV as deﬁned by Amsel’s criteria of having 3 of the 4 clinical signs.
{Laboratory BV as deﬁned by Nugent score 46.
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loss of lactobacillus.
To further elucidate the clinical manifestations
of each proﬁle, the frequency of individual
clinical signs was examined by proﬁle (Figure
1). Proﬁle C, which has low Lactobacillus but
otherwise resembles Proﬁle A, had few abnormal
clinical signs except for a high frequency of
abnormal vaginal pH, Characteristic of a post-
antibiotic vaginal ﬂora. Substantial changes in
clinical spectrum were seen in proﬁles D and F
which retained high Lactobacillus but also had
Gardnerella or both Gardnerella and Mobiluncus
morphotypes; each of the four clinical signs was
present in at least 40% of the occurrences of these
proﬁles. Abnormal clinical signs, particularly
increased pH, were further increased among
proﬁles G and H, which closely resemble classic
BV. The difference between proﬁles D and F, the
presence of Mobiluncus, does not appear to have a
strong association with the presence of clinical
signs. The same pattern holds when comparing
proﬁles G and H, even though Lactobacillus levels
are low. Comparing proﬁles G and H to D and F
reveals an increase in elevated pH, again asso-
ciated with a loss of Lactobacillus.
DISCUSSION
Our morphotypic proﬁles used the three mor-
photypes used to diagnose BV by the Gram stain
(Lactobacillus, Gardnerella, and Mobiluncus) char-
acterized the spectrum of vaginal ﬂora in this
cohort. In comparison of the proﬁles to clinical
BV diagnosis, the percentage of visits with clinical
BV as well as the frequency of the individual
clinical signs, increased as the vaginal ﬂora shifted
away from normal/healthy. The large increases in
frequency of elevated pH seen in proﬁles C, G,
and H illustrate the central role of Lactobacillus in
maintaining low vaginal pH. The increase in
clinical signs in proﬁles D and F suggests that the
presence of high Gardnerella plays an important
role in causing clinical signs, even in the presence
of high levels of Lactobacillus.
In addition, the deﬁned morphotypic proﬁles
clearly correlate with clinical signs. These associa-
tions, however, were not absolute. For example,
the full range of clinical signs was seen in women
with Gardnerella in both the presence and absence
of Lactobacillus, although clinical signs were more
common in the latter group of women. At least
some women within each morphotypic proﬁle
Figure 1 Prevalence of clinical signs by morphotypic proﬁle
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diagnosed as BV have the potential to differ
greatly depending on the diagnostic method
employed.
Our analysis did not assess host factors related
to BV. Optimal prediction of adverse outcomes
requires information on both vaginal microﬂora
and host responses. Because this data set has few
outcomes (most notably no obstetric data), no
other vaginal symptoms, and limited behavioral
factors, we were unable to assess the utility of
these proﬁles in predicting adverse outcomes.
Finally, the fact that all the women in this study
had risk factors for acquiring HIV and other STDs
may limit the generalizability of our ﬁndings.
Our large, multi-site, prospective study eval-
uated women using standardized protocols for
both clinical and lab BV diagnostic strategies and
centralized readings of all Gram stains. The
laboratory diagnosis of BV (interpretation of the
Gram stain by the Nugent score) is considered the
gold standard in most research settings but is
difﬁcult to conduct in clinical settings.
Additionally, the Nugent scoring system con-
ﬂates women with potentially very different
microﬂora in a single category. This study takes
the Gram stain data beyond the Nugent score,
highlighting proﬁles such as G, H, and F. One can
have a Nugent score of 7 to 10 with or without
the presence of Mobiluncus, and some patients
have high numbers of Gardnerella and Mobiluncus
while retaining Lactobacillus-like organisms. This
study also emphasizes the occurrence of large
numbers of women with abnormal or intermedi-
ate ﬂora. These points serve to remind us that BV
is not a pure, homogenous entity and is difﬁcult
to diagnose by any current method.
BV has been an elusive vaginal condition for
both researchers and clinicians. The response to
therapy is not uniform, the correlation with
complications is variable, randomized control
trials designed to eradicate BV and prevent
complications have resulted in contradictory
results, and discrepancies exist between Amsel
and Nugent diagnostic methods.
Our results represent an attempt to break down
the patterns of abnormal vaginal ﬂora into more
meaningful categories. Our data point to the need
for further research using the morphotypic
proﬁles in other samples of women and for
examination of their association with obstetric
outcomes. It is promising that by further
elucidating the morphotypic make-up of the
vaginal ﬂora, beyond what is possible with the
current data available for this analysis, a diagnostic
system can be articulated that better correlates
with risk factors for and outcomes of abnormal-
ities in vaginal ﬂora.
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